Today: 1 May 2026
Browse Category

NYSE:MRK 28 November 2025 - 15 December 2025

Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

Merck shares traded near $99.59 Monday afternoon, down 0.23%, after Bank of America raised its price target to $120 and reiterated a Buy rating. The move followed a positive European CHMP opinion on Winrevair and a higher dividend as the stock hit its ex-dividend date. Investors weighed these developments against ongoing regulatory scrutiny and questions about Merck’s post-Keytruda strategy.
15 December 2025
··
Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck shares closed at $100.30 on Dec. 12, ahead of the Dec. 15 ex-dividend date for a $0.85 quarterly payout. The stock sits 5.2% below its 52-week high, with Friday’s volume at 11.8 million shares, under the 50-day average. Investors are watching the impact of the dividend reset and ongoing developments around Keytruda and RSV products.
14 December 2025
·
Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck shares closed at $100.30 on Friday, up 1.3% for the day and 0.6% for the week, rebounding after early losses tied to vaccine-policy headlines and RSV therapy scrutiny. The stock gained despite broad market declines. Merck received a positive EU CHMP opinion for expanded use of Winrevair, while the FDA launched new safety reviews of its RSV preventive therapies for infants.
13 December 2025
··
Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck shares rose 0.69% to $99.69 by midday Friday after the European Medicines Agency’s CHMP recommended expanded approval for WINREVAIR in pulmonary arterial hypertension. The stock remains about 6% below its late-November high. Investors weighed the regulatory boost against ongoing legal issues for Keytruda and shifting vaccine policy headlines. Merck expects a final EU decision on WINREVAIR in early 2026.
12 December 2025
···
Merck (MRK) Stock News, Forecasts & Analyst Outlook — What Investors Are Watching on December 12, 2025

Merck (MRK) Stock News, Forecasts & Analyst Outlook — What Investors Are Watching on December 12, 2025

Merck shares closed at $99.01 on December 11, up 1.42% but still trailing some large pharma peers and remaining about 6% below last month’s high. Analyst upgrades and higher price targets from Wells Fargo, Goldman Sachs, and others have boosted sentiment, while the FDA’s new safety review of RSV antibodies, including Merck’s Enflonsia, adds regulatory uncertainty.
12 December 2025
·
Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck shares traded near $97.31 Wednesday afternoon, up slightly after Tuesday’s 2% drop. Volume topped 3.2 million as investors tracked dividend moves and new analyst upgrades. The stock remains about 25% below 2024 highs despite a 41% six-month rally. Signs of rising competition to Keytruda and looming patent pressures weighed on sentiment.
10 December 2025
··
Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck shares traded near $97.27 late December 10, 2025, up about 20% over the past month on strong clinical trial results and optimism for new products like Winrevair. Analysts at HSBC, Guggenheim, Scotiabank, and Goldman Sachs raised 12-month price targets to $120–$125. Merck’s market value stands at $240–245 billion, with a dividend yield of about 3.4–3.6%.
10 December 2025
···
Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Merck shares closed down 2.06% at $96.89 on December 9, 2025, with volume spiking to 15.3 million shares. The drop followed news that Formycon and Zydus Lifesciences will partner on a biosimilar to Merck’s top-selling cancer drug Keytruda, targeting the U.S. and Canada. Keytruda generated $29.5 billion in 2024 sales. Merck and JPMorgan were among the biggest drags on the Dow, which fell 0.8%.
10 December 2025
··
Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

Merck shares closed at $99.72 on Friday, down 1.16%, with volume above average. The stock sits about 6% below its November 52-week high and trades at roughly 13 times trailing earnings, with a dividend yield of 3.3–3.5%. A German court blocked Merck’s launch of subcutaneous Keytruda, citing patent infringement claims by Halozyme.
8 December 2025
··
Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck closed an $8 billion senior notes offering, likely to help fund its $9.2 billion Cidara Therapeutics acquisition. The company also reported new regulatory wins and raised its dividend, but faced a patent setback for subcutaneous Keytruda in Germany. Merck shares ended December 5 at $99.72, down 1.2%, and remain near the top of their 52-week range. Trading volume was above average.
7 December 2025
···
Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

Merck shares closed at $100.86 on December 4, down 1.4%, with after-hours trading flat. Scotiabank raised its price target to $120, echoing similar moves by Goldman Sachs and Wells Fargo. Keytruda sales rose 10% in Q3 to $8.1 billion, but Gardasil fell 24% amid weaker China demand. The stock’s market cap stands near $250 billion.
4 December 2025
··
Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck shares traded near $101 on December 2, 2025, down about 1%, with a market cap above $250 billion after a 22% rally in November. The company raised its quarterly dividend to $0.85 per share, effective January 2026. Merck’s stock remains below its 52-week high of $105.84 and trades at a forward P/E of 11–11.5x, below sector averages.
2 December 2025
···
Merck Stock (MRK) in November 2025: Price, Latest News, Forecasts and Analyst Outlook

Merck Stock (MRK) in November 2025: Price, Latest News, Forecasts and Analyst Outlook

Merck & Co. shares closed at $104.83 on Nov. 28, near a 52-week high after a surge from the mid-$80s earlier in the month. The rally followed U.S. and European approvals for new Keytruda cancer drug formulations and positive trial results for Winrevair. Merck was a top contributor to the Dow’s late November gains. The stock is up about 8–9% in 2025 including dividends.
30 November 2025
·
Merck Stock (MRK) Outlook Before the December 1, 2025 Market Open: Rally, Ratings and Pipeline Catalysts

Merck Stock (MRK) Outlook Before the December 1, 2025 Market Open: Rally, Ratings and Pipeline Catalysts

Merck closed at $104.83 on November 28, near its 52-week high, after gaining about 22% in November. Trading volume approached 6 million shares, with an after-hours quote at $104.74. Analysts cited strong earnings, dividend growth, and a diversified pipeline beyond Keytruda as key drivers. Merck’s five-year beta stands at 0.32, indicating lower volatility than the broader market.
30 November 2025
·
Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck shares closed at $104.83 on November 28, 2025, near their 52-week high after a 22% surge in the past month. The stock spent much of early autumn in the mid-$80s before jumping above $100 following third-quarter earnings and positive November news. Analysts are split on valuation, with some models showing MRK as fairly priced and others suggesting significant upside.
30 November 2025
··
Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck shares closed at $104.83 on November 28, just below the 52-week high of $105.84 set earlier in the week after a Wells Fargo upgrade. The stock is up about 21% over the past month and 8% year-to-date. Scotia Capital and Level Four Advisory Services have trimmed their Merck holdings, according to new filings. Merck continues to warn investors about an unsolicited mini-tender offer from Tutanota LLC at $65 per share.
29 November 2025
·
Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck shares closed near $104.5 on Friday, close to a 52-week high, with market cap near $260 billion. Norges Bank disclosed a new $2.86 billion stake, while Groupama, SEB, and Boston Partners trimmed holdings. The stock jumped 21% in the past month, buoyed by new oncology approvals and bullish research. Merck’s trailing 12-month revenue stands at about $64 billion, with net income near $19 billion.
28 November 2025
···
1 … 4 5 6 7

Stock Market Today

  • Stock futures dip after mixed earnings from Microsoft and Meta; S&P 500 hits record high
    May 1, 2026, 6:24 AM EDT. Stocks surged Thursday with the S&P 500 closing above 7,200 for the first time, reaching an all-time high driven by strong earnings from Caterpillar and Alphabet. Caterpillar's nearly 10% jump and positive outlook suggest resilience despite lackluster U.S. economic growth in Q1. Alphabet's revenue beat and increased 2026 capital spending also buoyed markets. However, Meta and Microsoft shares declined 8.6% and 3.9%, respectively, due to rising capital expenditure concerns and disappointing user growth. Experts remain cautious about long-term tech valuations amid heavy investment in AI infrastructure. Still, April marked a strong month for major indices: the S&P 500 up 10.4%, Nasdaq 15.3%, and Dow 7.1%, signaling investor optimism despite underlying uncertainties.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 6:31 AM EDT Stock futures dip after mixed earnings from Microsoft and Meta; S&P 500 hits record high May 1, 2026, 6:24 AM EDT. Stocks surged Thursday with the S&P 500 closing above 7,200 for the first time, reaching an all-time high driven by strong earnings from Caterpillar and Alphabet. Caterpillar's nearly 10% jump and positive outlook suggest resilience despite lackluster U.S. economic growth in Q1. Alphabet's revenue beat and increased 2026 capital spending also buoyed markets. However, Meta and Microsoft shares declined 8.6% and 3.9%, respectively, due
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Go toTop